Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas

Abstract

BackgroundLow absolute lymphocyte count (ALC) has previously been established as a marker of poor prognosis in multiple cancer types. There is growing evidence that ALC may also be associated with response to immunotherapy. This study explores whether response to PD1 inhibitors in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is associated with pretreatment ALC.MethodsThirty-four R/M HNSCC patients who received either nivolumab or pembrolizumab between January 2014 and May 2018 at Johns Hopkins were identified retrospectively. Pretreatment blood counts in patients with and without clinical benefit from PD1 inhibitors were compared. Time-to-progression analyses were performed by dichotomizing the study cohort with the threshold of ALC 600 cells/μl, which is approximately 1.5 standard deviations away from treatment-naïve baseline mean.ResultsPatients with lower ALC appeared to have significantly less clinical benefit from anti-PD1 therapy. Those patients with pretreatment ALC < 600 cells/μl also had shorter PFS than patients with pretreatment ALC ≥ 600 cells/μl (median PFS 60 days vs. 141 days, p < 0.05). These results were consistent with multivariate proportional hazards analyses demonstrating significant association with progression. These observations were further supported by an expansion cohort analysis incorporating additional fourteen R/M HNSCC patients who received other checkpoint immunotherapy regimens at our institution.ConclusionsThis study for the first time demonstrates that pretreatment ALC is significantly associated with response to PD1 inhibitors in R/M HNSCC patients.Electronic supplementary materialThe online version of this article (10.1186/s40425-018-0395-x) contains supplementary material, which is available to authorized users.

Prognostic significance of neutrophil‐to‐lymphocyte ratio in HPV status era for oropharyngeal cancer

“…These findings suggest that these less expensive and easily TA B L E 2 Modification of haematological biomarkers before and after chemoradiotherapy (Balkwill & Mantovani, 2001). Low lymphocyte counts can indicate immunosuppression in patients with cancer and may be related to the limited effect of cancer immunotherapy (Ho et al, 2018).…”

Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response

“…Other studies have established RIL as a negative prognostic factor [33,34]. Furthermore, lymphopenia can reduce the efficacy of ICIs [35,36]. In a retrospective study of 167 patients treated with Nivolumab or Pembrolizumab, baseline and 3-month lymphopenia were associated with shorter PFS [35].…”

Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab

“…Some studies have evaluated the value of some blood cell count indexes, particularly the neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR) and demonstrated these biomarkers have the prognostic role in different tumors include NSCLC . Recently, several studies suggested that NLR and PLR also strongly associated with poor clinical outcomes in patients treated with ICIs . Systemic immune‐inflammation index (SII) is a novel inflammatory marker which combines NLR and platelet is an independent risk factor for the development of solid cancer .…”